{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T09:59:05Z","timestamp":1781344745243,"version":"3.54.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T00:00:00Z","timestamp":1766620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T00:00:00Z","timestamp":1766620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00428-025-04359-0","type":"journal-article","created":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T15:28:08Z","timestamp":1766676488000},"page":"1405-1415","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Addressing HER2 IHC scoring discrepancies in endometrial serous carcinoma: a comparative analysis with reflex ISH"],"prefix":"10.1007","volume":"488","author":[{"given":"Maria Gaia","family":"Mastrosimini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"d\u2019Amati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Angelico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Bogina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bortesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Zamboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4473-7560","authenticated-orcid":false,"given":"Gian Franco","family":"Zannoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pesci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,25]]},"reference":[{"key":"4359_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2007.08.075","volume":"198","author":"SM Ueda","year":"2008","unstructured":"Ueda SM, Kapp DS, Cheung MK, Shin JY, Osann K, Husain A et al (2008) Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol 198:218.e1-6. https:\/\/doi.org\/10.1016\/j.ajog.2007.08.075","journal-title":"Am J Obstet Gynecol"},{"key":"4359_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/GCO.0b013e328334d8a3","volume":"22","author":"AN Fader","year":"2010","unstructured":"Fader AN, Boruta D, Olawaiye AB, Gehrig PA (2010) Uterine papillary serous carcinoma: epidemiology, pathogenesis and management. Curr Opin Obstet Gynecol 22:21\u201329. https:\/\/doi.org\/10.1097\/GCO.0b013e328334d8a3","journal-title":"Curr Opin Obstet Gynecol"},{"key":"4359_CR3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/IGC.0000000000000844","volume":"27","author":"M McGunigal","year":"2017","unstructured":"McGunigal M, Liu J, Kalir T, Chadha M, Gupta V (2017) Survival differences among uterine papillary serous, clear cell and grade 3 endometrioid adenocarcinoma endometrial cancers: a National Cancer Database analysis. Int J Gynecol Cancer 27:85\u201392. https:\/\/doi.org\/10.1097\/IGC.0000000000000844","journal-title":"Int J Gynecol Cancer"},{"key":"4359_CR4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.ygyno.2008.11.014","volume":"112","author":"HD Homesley","year":"2009","unstructured":"Homesley HD, Filiaci V, Gibbons SK, Long HJ, Cella D, Spirtos NM et al (2009) A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol 112:543\u201352. https:\/\/doi.org\/10.1016\/j.ygyno.2008.11.014","journal-title":"Gynecol Oncol"},{"key":"4359_CR5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S1470-2045(18)30079-2","volume":"19","author":"SM de Boer","year":"2018","unstructured":"de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C et al (2018) Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 19:295\u2013309. https:\/\/doi.org\/10.1016\/S1470-2045(18)30079-2","journal-title":"Lancet Oncol"},{"key":"4359_CR6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ygyno.2005.07.124","volume":"100","author":"CA Livasy","year":"2006","unstructured":"Livasy CA, Reading FC, Moore DT, Boggess JF, Lininger RA (2006) EGFR expression and HER2\/neu overexpression\/amplification in endometrial carcinosarcoma. Gynecol Oncol 100:101\u20136. https:\/\/doi.org\/10.1016\/j.ygyno.2005.07.124","journal-title":"Gynecol Oncol"},{"key":"4359_CR7","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s00428-021-03017-5","volume":"478","author":"H Yoshida","year":"2021","unstructured":"Yoshida H, Nishikawa T, Matsumoto K, Mori M, Hirashima Y, Takehara K et al (2021) Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy. Virchows Arch 478:1161\u20131171. https:\/\/doi.org\/10.1007\/s00428-021-03017-5","journal-title":"Virchows Arch"},{"key":"4359_CR8","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/PAS.0000000000001870","volume":"46","author":"TM Jenkins","year":"2022","unstructured":"Jenkins TM, Cantrell LA, Stoler MH, Mills AM (2022) HER2 overexpression and amplification in uterine carcinosarcomas with serous morphology. Am J Surg Pathol 46:435\u2013442. https:\/\/doi.org\/10.1097\/PAS.0000000000001870","journal-title":"Am J Surg Pathol"},{"key":"4359_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ygyno.2020.07.016","volume":"159","author":"BK Erickson","year":"2020","unstructured":"Erickson BK, Najjar O, Damast S, Blakaj A, Tymon-Rosario J, Shahi M et al (2020) Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: a multi-institutional cohort study. Gynecol Oncol 159:17\u201322. https:\/\/doi.org\/10.1016\/j.ygyno.2020.07.016","journal-title":"Gynecol Oncol"},{"key":"4359_CR10","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","volume":"36","author":"AN Fader","year":"2018","unstructured":"Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O et al (2018) Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu. J Clin Oncol 36:2044\u201351. https:\/\/doi.org\/10.1200\/JCO.2017.76.5966","journal-title":"J Clin Oncol"},{"key":"4359_CR11","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.1158\/1078-0432.CCR-20-0953","volume":"26","author":"AN Fader","year":"2020","unstructured":"Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O et al (2020) Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage iii-iv) or recurrent uterine serous carcinomas that overexpress Her2\/Neu (NCT01367002): updated overall survival analysis. Clin Cancer Res 26:3928\u20133935. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0953","journal-title":"Clin Cancer Res"},{"key":"4359_CR12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.6004\/jnccn.2023.0006","volume":"21","author":"N Abu-Rustum","year":"2023","unstructured":"Abu-Rustum N, Yashar C, Arend R, Barber E, Bradley K, Brooks R et al (2023) Uterine neoplasms, version 1.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 21:181\u2013209. https:\/\/doi.org\/10.6004\/jnccn.2023.0006","journal-title":"J Natl Compr Canc Netw"},{"key":"4359_CR13","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/gcc.22113","volume":"52","author":"N Buza","year":"2013","unstructured":"Buza N, Hui P (2013) Marked heterogeneity of HER2\/NEU gene amplification in endometrial serous carcinoma. Genes Chromosomes Cancer 52:1178\u20131186. https:\/\/doi.org\/10.1002\/gcc.22113","journal-title":"Genes Chromosomes Cancer"},{"key":"4359_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam F, Makker V, Oaknin A, Oh D-Y, Banerjee S, Gonz\u00e1lez-Mart\u00edn A et al (2024) Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol 42:47\u201358. https:\/\/doi.org\/10.1200\/JCO.23.02005","journal-title":"J Clin Oncol"},{"key":"4359_CR15","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1038\/modpathol.2013.113","volume":"26","author":"N Buza","year":"2013","unstructured":"Buza N, English DP, Santin AD, Hui P (2013) Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. Mod Pathol 26:1605\u201312. https:\/\/doi.org\/10.1038\/modpathol.2013.113","journal-title":"Mod Pathol"},{"key":"4359_CR16","unstructured":"Turashvili G, Karnezis AN, Crothers B et al (n.d.)Template for reporting results of biomarker testing of specimens from patients with carcinoma of gynecologic origin version: College of American Pathologists (CAP). 1.2.0.0 Protocol Posting Date: December 2024. Accessed January 11, 2025: https:\/\/documents.cap.org\/protocols\/Gynecologic.Bmk_1.2.0.0.-REL.CAPCP.pdf?_gl= 1*1o5n1mv*_ga*OTE0OTU3NzMyLjE3MjI0NzU5Mzg.*_ga_97ZFJSQQ0X*MTczNzU4N- TAyMS4xNC4xLjE3Mzc1ODUwNTAuMC4wLjA."},{"key":"4359_CR17","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS et al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol 36:2105\u201322. https:\/\/doi.org\/10.1200\/JCO.2018.77.8738","journal-title":"J Clin Oncol"},{"key":"4359_CR18","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.22.02864","volume":"41","author":"AC Wolff","year":"2023","unstructured":"Wolff AC, Somerfield MR, Dowsett M, Hammond MEH, Hayes DF, McShane LM et al (2023) Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update. J Clin Oncol 41:3867\u201372. https:\/\/doi.org\/10.1200\/JCO.22.02864","journal-title":"J Clin Oncol"},{"key":"4359_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/PGP.0000000000000711","volume":"40","author":"N Buza","year":"2021","unstructured":"Buza N (2021) HER2 testing and reporting in endometrial serous carcinoma: practical recommendations for HER2 immunohistochemistry and fluorescent in situ hybridization: proceedings of the ISGyP companion society session at the 2020 USCAP annual meeting. Int J Gynecol Pathol 40:17. https:\/\/doi.org\/10.1097\/PGP.0000000000000711","journal-title":"Int J Gynecol Pathol"},{"key":"4359_CR20","doi-asserted-by":"publisher","first-page":"687","DOI":"10.5858\/arpa.2020-0207-RA","volume":"145","author":"N Buza","year":"2021","unstructured":"Buza N (2021) HER2 testing in endometrial serous carcinoma: time for standardized pathology practice to meet the clinical demand. Arch Pathol Lab Med 145:687\u2013691. https:\/\/doi.org\/10.5858\/arpa.2020-0207-RA","journal-title":"Arch Pathol Lab Med"},{"key":"4359_CR21","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","volume":"35","author":"AN Bartley","year":"2017","unstructured":"Bartley AN, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson AB et al (2017) HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol 35:446\u201364. https:\/\/doi.org\/10.1200\/JCO.2016.69.4836","journal-title":"J Clin Oncol"},{"key":"4359_CR22","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.5858\/arpa.2022-0229-CP","volume":"147","author":"IS Hagemann","year":"2023","unstructured":"Hagemann IS, Bridge JA, Tafe LJ, Hameed MR, Moncur JT, Bellizzi AM et al (2023) Current laboratory testing practices for assessment of ERBB2\/HER2 in endometrial serous carcinoma and colorectal carcinoma. Arch Pathol Lab Med 147:1148\u201357. https:\/\/doi.org\/10.5858\/arpa.2022-0229-CP","journal-title":"Arch Pathol Lab Med"},{"key":"4359_CR23","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1097\/PAS.0000000000002392","volume":"49","author":"E Menshikova","year":"2025","unstructured":"Menshikova E, Deeb K, Genega EM, Hanley K, Turashvili G (2025) Comparison of HER2 scoring systems in endometrial cancer: toward optimization of HER2-directed therapies. Am J Surg Pathol 49:674\u2013685. https:\/\/doi.org\/10.1097\/PAS.0000000000002392","journal-title":"Am J Surg Pathol"},{"key":"4359_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ygyno.2025.02.005","volume":"194","author":"A Cort\u00e9s-Salgado","year":"2025","unstructured":"Cort\u00e9s-Salgado A, Moreno-Moreno E, Carretero-Barrio I, Caniego-Casas T, Crist\u00f3bal E, Del Campo-Albendea L et al (2025) HER2 expression in a molecularly defined cohort of endometrial cancer patients: the SPECTRUM study. Gynecol Oncol 194:33\u201340. https:\/\/doi.org\/10.1016\/j.ygyno.2025.02.005","journal-title":"Gynecol Oncol"},{"key":"4359_CR25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s44276-025-00125-6","volume":"3","author":"K Aro","year":"2025","unstructured":"Aro K, Loukovaara M, B\u00fctzow R, Pasanen A (2025) HER2 amplification and HER2 low expression in endometrial carcinoma: prevalence across molecular, histological and clinicopathological risk groups. BJC Rep 3:8. https:\/\/doi.org\/10.1038\/s44276-025-00125-6","journal-title":"BJC Rep"},{"key":"4359_CR26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ygyno.2025.03.012","volume":"195","author":"J Salinaro","year":"2025","unstructured":"Salinaro J, Singh K, Sands N, Gill V, Perati S, James N et al (2025) Distribution and concordance of HER2 scores in endometrial and ovarian cancer. Gynecol Oncol 195:115\u201321. https:\/\/doi.org\/10.1016\/j.ygyno.2025.03.012","journal-title":"Gynecol Oncol"},{"key":"4359_CR27","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","volume":"25","author":"AC Wolff","year":"2007","unstructured":"Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ et al (2007) American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118\u201345. https:\/\/doi.org\/10.1200\/JCO.2006.09.2775","journal-title":"J Clin Oncol"},{"key":"4359_CR28","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41379-020-00695-5","volume":"34","author":"CL Robinson","year":"2021","unstructured":"Robinson CL, Harrison BT, Ligon AH, Dong F, Maffeis V, Matulonis U et al (2021) Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays. Mod Pathol 34:603\u201312. https:\/\/doi.org\/10.1038\/s41379-020-00695-5","journal-title":"Mod Pathol"},{"key":"4359_CR29","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1038\/s41379-021-00746-5","volume":"34","author":"N Buza","year":"2021","unstructured":"Buza N, Euscher ED, Matias-Guiu X, McHenry A, Oliva E, Ordulu Z, Elsevier et al (2021) Reproducibility of scoring criteria for HER2 immunohistochemistry in endometrial serous carcinoma: a multi-institutional interobserver agreement study. Mod Pathol 34:1194\u2013202. https:\/\/doi.org\/10.1038\/s41379-021-00746-5","journal-title":"Mod Pathol"},{"key":"4359_CR30","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1007\/s00535-018-1464-0","volume":"53","author":"T Wakatsuki","year":"2018","unstructured":"Wakatsuki T, Yamamoto N, Sano T, Chin K, Kawachi H, Takahari D et al (2018) Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer. J Gastroenterol 53:1186\u20131195. https:\/\/doi.org\/10.1007\/s00535-018-1464-0","journal-title":"J Gastroenterol"},{"key":"4359_CR31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/ajcp\/aqz010","volume":"152","author":"KE Muller","year":"2019","unstructured":"Muller KE, Marotti JD, Tafe LJ (2019) Pathologic features and clinical implications of breast cancer with HER2 intratumoral genetic heterogeneity. Am J Clin Pathol 152:7\u201316. https:\/\/doi.org\/10.1093\/ajcp\/aqz010","journal-title":"Am J Clin Pathol"},{"key":"4359_CR32","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.humpath.2007.05.004","volume":"38","author":"RD Powell","year":"2007","unstructured":"Powell RD, Pettay JD, Powell WC, Roche PC, Grogan TM, Hainfeld JF et al (2007) Metallographic in situ hybridization. Hum Pathol 38:1145\u201359. https:\/\/doi.org\/10.1016\/j.humpath.2007.05.004","journal-title":"Hum Pathol"},{"key":"4359_CR33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, DESTINY-Breast04 Trial Investigators, Massachusetts Medical Society et al (2022) Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387:9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690","journal-title":"N Engl J Med"},{"key":"4359_CR34","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1200\/JCO.19.02488","volume":"38","author":"P Tarantino","year":"2020","unstructured":"Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E et al (2020) HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol 38:1951\u201362. https:\/\/doi.org\/10.1200\/JCO.19.02488","journal-title":"J Clin Oncol"},{"key":"4359_CR35","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.semcancer.2020.02.016","volume":"72","author":"C Marchi\u00f2","year":"2021","unstructured":"Marchi\u00f2 C, Annaratone L, Marques A, Casorzo L, Berrino E, Sapino A (2021) Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond. Semin Cancer Biol 72:123\u2013135. https:\/\/doi.org\/10.1016\/j.semcancer.2020.02.016","journal-title":"Semin Cancer Biol"},{"key":"4359_CR36","doi-asserted-by":"publisher","DOI":"10.1097\/PGP.0000000000001115","author":"A McHenry","year":"2025","unstructured":"McHenry A, Liang B, Hammer PM, Libert D, Mack T, Tokuyama M et al (2025) Comparison of endometrial serous and gastric HER2 immunohistochemistry scoring schemes in endometrial carcinomas with Aberrant p53 expression: reproducibility and in situ hybridization correlation. Int J Gynecol Pathol. https:\/\/doi.org\/10.1097\/PGP.0000000000001115","journal-title":"Int J Gynecol Pathol"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04359-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-025-04359-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04359-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T09:54:25Z","timestamp":1781344465000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-025-04359-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,25]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4359"],"URL":"https:\/\/doi.org\/10.1007\/s00428-025-04359-0","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,25]]},"assertion":[{"value":"27 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with Good Clinical Practice guidelines, the Declaration of Helsinki, and current laws and regulations. The protocol was approved by the Institutional Review Boards of both participating institutions, with a single approval code (n. 16675) issued by the IRCCS Ospedale Sacro Cuore Don Calabria (Negrar, Verona), which covered both centers. Written informed consent for participation and publication was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}